Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Abstract

A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity. Another method is based upon gene expression predictive biomarkers assessed via RNA expression in peripheral blood cell samples collected prior to treatment with the compound, which is also used for treating patients afflicted with pancreatic cancer.

Description

technical field [0001] The present invention relates to a method for treating a patient suffering from cancer with a tyrosine kinase inhibitor, a mast cell inhibitor or a c-Kit inhibitor, in particular masitinib, optionally in combination with at least one The patient is treated with a combination of antineoplastic agents. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor and optionally at least one antineoplastic agent are administered in a dosage regimen comprising a therapeutically effective amount. The invention also relates to methods for predicting therapeutic response to said therapy in a given patient and thus identifying applicable subgroups of patients based on these predictive factors; these predictive factors are sometimes referred to as predictive biomarkers. One approach is based on clinical markers of pain intensity. The second method is based on the evaluation of RNA expression in peripheral blood cell samples collected prior to treatment ...

AI Technical Summary

Problems solved by technology

The Folfirinox program provides an alternative framework (backbone) for the development of combination therapies, but high toxicity will likely limit its use in most patients

The persistent poor prognosis and lack of effective treatments for pancreatic cancer, especially pain-related pancreatic cancer, underscores the unmet medical need for more effective therapeutic strategies that improve the clinical management of patients with pancreatic cancer without significantly increased toxicity

Images